Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: MarketLine (a Datamonitor Company)

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

H Lundbeck A/S announces results of Brintellix study

Monday, 16 Jun 2014 06:32am EDT 

H Lundbeck A/S:Announces results from CONNECT study showing that Brintellix (vortioxetine) 10 mg/day to 20 mg/day in adults with major depressive disorder (MDD) met the primary study endpoint of demonstrating superiority versus placebo in cognitive function as measured by the Digit Symbol Substitution Test (DSST).These findings will be presented as a late-breaking poster at the 29th International College of Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada June 24.The study also met several secondary endpoints measuring symptoms of depression and patient outcomes; Brintellix was generally well tolerated.The study results are consistent with results from previous studies of Brintellix that demonstrated an improvement in cognitive performance in adult and in elderly patients with major depression. 

Company Quote

2.8 +2.23%
19 Sep 2014